Protein Needs Study

Overview

Severe muscle loss in patients with cancer has been associated with increased physical disability, extended hospitalization, infectious and noninfectious complications, increased risk of severe toxicity during cancer treatment, poor quality of life and shortened survival. Adequate protein is key to sustain muscle mass and overall health. However, current nutritional recommendations are not specific or evidence-based. The aim of this project is to determine the protein needs of patients with colorectal or breast cancer. Protein needs will be determined using a novel, non-invasive approach. Our results will inform nutritional recommendations and guidelines with the ultimate goal of improving outcomes for people with cancer.

Full Title of Study: “Innovative Approaches to the Lack of Evidence-based Dietary Protein Requirements for Patients With Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2024

Interventions

  • Dietary Supplement: Phenylalanine intake
    • Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein-free cookies and 4 labeled amino acid experimental meals.

Arms, Groups and Cohorts

  • Experimental: Phenylalanine intake

Clinical Trial Outcome Measures

Primary Measures

  • 13C Phenylalanine Oxidation
    • Time Frame: 8.5 hours
    • Breath, urine and blood samples will be collected during the study to measure the rate of oxidation of 13C phenylalanine.

Participating in This Clinical Trial

Inclusion Criteria

  • Outpatients age 45-80 years; – Patients attending the new patient clinic at the Cross Cancer Institute with a diagnosis of colorectal cancer or breast cancer (stages II to III); – Able to complete baseline visits within approximately 4 weeks of starting chemotherapy OR after a minimum of 4 weeks post-surgery if not undergoing chemotherapy; – Ambulatory. Exclusion Criteria:

  • Premenopausal women due to impact on protein requirements; – Received anti-cancer hormone treatment or immunotherapy in the 4 weeks before first baseline visit; – Renal impairment based on a creatinine clearance for estimated glomerular filtration rate (eGFR) of <60 mL/min – Abnormal glucose metabolism based on a fasting glucose level >6mmol/L and an HbA1c >5.7% or as reviewed by study team; – Comorbidities or medications that would interfere with the participants ability to follow the study protocol or the quality of the data(e.g. diabetes, class III obesity, hormone therapy, another active cancer diagnosis); – Unable/unwilling to provide urine, breath and blood samples (e.g. oxygen tank, catheter, etc.); – Unable to eat the meals provided (i.e. receiving parenteral or enteral nutrition, severe allergies); – Substance dependent (e.g. alcohol, cigarettes, illicit drugs) and unable to follow study protocols.

Gender Eligibility: All

Minimum Age: 45 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Alberta
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Carla Prado, PhD, RD, Principal Investigator, University of Alberta
  • Overall Contact(s)
    • Anne Caretero, RD, 780-492-7820, caretero@ualberta.ca

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.